Today Wave Neuro received a generous $1.5 million grant from the Engelstad Foundation that will support Phase Two of the clinical trial currently underway with Texas A&M University Health Science Center (Texas A&M Health) Institute of Biosciences and Technology. This significant contribution will accelerate the trial, which aims to develop and validate innovative treatments for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI). Wave Neuroscience is at the forefront of developing personalized non-invasive therapies for mental health conditions. Their ongoing FDA trial will evaluate the effectiveness of their pioneering technology, Magnetic EEG-guided Resonance Therapy™ (MeRT™) in treating PTSD and TBI. With this generous funding from the Engelstad Foundation, Wave Neuroscience will be able to accelerate the trial and potentially pave the way for groundbreaking treatment options.
"We are deeply grateful for the Engelstad Foundation's incredible generosity and support," said Fred Walke, Wave’s CEO.
"Their donation will significantly accelerate our efforts to bring new, effective treatments to individuals suffering from PTSD and TBI. We look forward to the potential impact this will have on mental health care."
The Engelstad Foundation is committed to making a difference in the community and improving the lives of individuals through its philanthropic endeavors. This donation is a testament to the Foundation's commitment to fostering innovation and supporting valuable health initiatives. “Wave Neuroscience is on the frontlines with such a compassionate mission - to help improve the lives of those with PTSD and TBI,” says Kris Engelstad, trustee of the Engelstad Foundation. “We see this grant as not only an investment in Wave Neuroscience’s incredible treatment efforts and research, but the ultimate wellbeing of so many out there.” PTSD can result from experiencing or witnessing a traumatic event, and the symptoms put a person at greater risk for depression, substance abuse, and a host of psychological disorders. In 2020, approximately 13 million people were suffering from PTSD in the United States (National Center for PTSD). PTSD is often coupled with TBI, and there were approximately 214,110 TBI-related hospitalizations in 2020 (U.S. Centers for Disease Control).
If you are interested in financially supporting this groundbreaking work, please email Mary Callan, Ph.D., at mary@waveneuro.com, or call 949.229.0586.
If you are interested in enrolling in this trial or would like to learn more about it, please visit https://www.mertptsdtrial.com.
